Get the Stockscreener App
0.3045
10.43%
-0.0388
Vivos Therapeutics Inc stock is traded at $0.3045, with a volume of 429.99K.
It is down -10.43% in the last 24 hours and down -26.70% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$0.3433
Open:
$0.305
24h Volume:
429.99K
Relative Volume:
0.19
Market Cap:
$4.23M
Revenue:
$19.57M
Net Income/Loss:
$-25.12M
P/E Ratio:
-0.1317
EPS:
-2.3114
Net Cash Flow:
$-19.71M
1W Performance:
-3.21%
1M Performance:
-26.70%
6M Performance:
-80.54%
1Y Performance:
-92.52%
1-Day Range:
$0.301
$0.3219
1-Week Range:
$0.271
$0.364
52-Week Range:
$0.271
$5.12
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.3046 | 4.77M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
110.19 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.55 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.78 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.60 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.88 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance
Vivos Therapeutics stock falls 6% on second quarter revenue miss - Investing.com
Vivos Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Vivos Therapeutics posts strong Q2 2026 revenue growth - Investing.com Canada
Transcript : Vivos Therapeutics, Inc., Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vivos Therapeutics Q2 revenue up 35% YoY; gross margin expands to 57% - scanx.trade
Vivos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com - Investing.com UK
Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results - Quiver Quantitative
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update - Yahoo! Finance Canada
Vivos Therapeutics Inc (NASDAQ: VVOS) Share Price, VVOS Stock News, VVOS Share Price & Updates - Kalkine
Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics schedules Q2 2026 results, conference call - scanx.trade
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call - marketscreener.com
Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn - Stock Titan
Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices - TipRanks
Vivos Oral Appliance Shows Improvement in Insomnia Severity - Sleep Review
Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS) - Stock Titan
Vivos partners with Greenway Health to deploy AI platform - Investing.com
Vivos partners with Greenway Health to deploy AI platform By Investing.com - Investing.com Nigeria
Vivos Therapeutics Expands AI Workflow Partnership With Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada - Moomoo
Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada - Quiver Quantitative
Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada - Stock Titan
Vivos Therapeutics partners with Greenway Health for AI deployment - scanx.trade
Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology - Yahoo Finance
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology - The Manila Times
Vivos sleep apnea devices gain broader protection after new patent - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Trending Stocks Today | Vivos Therapeutics Soars 36.3% Post-Market - Moomoo
Vivos Therapeutics (VVOS) Edges Up 1.71% to $0.42 as Stock Tests Range Between $0.40 Support and $0.44 ResistanceCovered Call Trade - dars.gov.et
Vivos Therapeutics appoints Roman Franklin as new CFO - scanx.trade
Price to sales forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Price to book forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.390|Chg%:-0.013 - TradingKey
Vivos Therapeutics, Inc. Revenue Breakdown – NASDAQ:VVOS - TradingView
Vivos Therapeutics Inc (VVOS) Balance Sheet - TradingKey
Vivos Therapeutics Inc (VVOS) Income Statement - TradingKey
Vivos Therapeutics Inc (VVOS) Cash Flow - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.395|Chg%:+0.002 - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):